Get Started in Minutes
How Kanjinti Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Kanjinti?
Kanjinti was first approved by the FDA in 2019 as a biosimilar of an already-marketed anticancer drug called Herceptin. It is classified under the pharmacologic category of antineoplastic, monoclonal antibodies, and anti-HER2 drug agents. The active substance of Kajinti is “trastuzumab-anns.”
This medication is intended to slow the growth of HER2 overexpressing metastatic gastric cancer and breast cancers (early and metastatic) in adults. HER2 cancers typically begin when the HER2 proteins grow and divide in an uncontrollable way leading to an overexpression of these proteins.
What Is Kanjinti Used To Treat?
Kanjinti has been approved for the labeled indications of metastatic gastric or gastroesophageal junction adenocarcinoma cancer, as well as breast cancer (both early and metastatic forms).
Kanjinti may be prescribed under the following conditions:
- In early breast cancer (where the cancer is localized within the breast and does not spread beyond the breast or lymph nodes to the other body parts). Kanjinti may be initiated after surgery, chemotherapy, and radiotherapy. It can be used as a single agent (if a patient has previously received chemotherapy) or combined with other chemotherapy drugs such as paclitaxel or docetaxel.
- In metastatic breast cancer (where the tumor has spread to other body parts), Kanjinti may be used alone if no other treatment has been shown to be effective. It can also be used in patients who have received one or more chemotherapy sessions. If patients have not received chemotherapy or any other therapy before, Kanjinti is used in combination with chemotherapy medicines (e.g., paclitaxel).
- In metastatic gastric (stomach) cancer, Kanjinti can be used alone or in combination with other chemotherapy drugs (cisplatin and capecitabine), especially in patients who have not received any prior treatment.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Kanjinti Side Effects
Listed below are some of the common adverse side effects patients may experience during or after receiving an infusion of Kanjinti.
In metastatic breast cancer settings, the most common side effects experienced by 10% or more of the patients include:
- Fever, chills, and cough
- Congestive heart failure
- Infections, headache, fatigue
- Vomiting and diarrhea
In metastatic gastric cancer settings, the most common side effects experienced by 10% or more of the patients include:
- Neutropenia, anemia
- Fever, diarrhea, weight loss
- Upper respiratory tract infections
- Low platelet count (thrombocytopenia)
- Changes in taste (dysgeusia)
- Mucosal inflammation
In severe and adverse cases, the following may occur:
- Pulmonary toxicity (damage to lungs)
- Embryo-fetal toxicity (usually occurs in patients who are pregnant and receiving Kanjinti infusion)
- Chemotherapy-induced neutropenia exacerbation
Kanjinti Dosage and Schedule
The dosage of Kanjinti is different for gastric cancer and breast cancer (both early and metastatic). The doses of Kanjinti are adjusted in these patients according to the following criteria:
- Patient’s body weight
- Expression of HER2 proteins
- Treatment plan: Will Kanjinti be given alone or in combination with adjuvant treatment (such as chemotherapy)?
- Treatment frequency: Will Kanjinti be given once weekly or once every three weeks?
Dosage for Early Breast Cancer
The recommended initial dose of Kanjinti for patients with early breast cancer who are also receiving chemotherapy is 4 mg/kg given intravenously for 90 minutes.
- Initial dose: If the first dose is well tolerated, then the IV infusion time is shortened to 30 minutes with a subsequent dose of 2 mg/kg weekly during chemotherapy for the first 12 weeks (for patients taking docetaxel or paclitaxel) or 18 weeks (for patients taking carboplatin and docetaxel).
- Patients usually complete a total of 52 weeks of therapy.
Dosage for Metastatic Breast Cancer
The initial dose of Kanjinti alone or in combination with paclitaxel is 4 mg/kg for 90 minutes of IV infusion, followed by the subsequent dose of 2 mg/kg every week for 30 minutes until disease progression.
Dosage for Metastatic Gastric Cancer
The starting dose of Kanjinti alone is 8 mg/kg over 90 minutes, followed by the subsequent dose of 6 mg/kg every 3 weeks for over 30 to 90 minutes until disease progression.